BLADDER CANCER THERAPEUTICS MARKET ANALYSIS

Market News

Key Developments

1. Market players are involved in various business strategies such as gaining product approval from regulatory authorities, in order expand their product portfolio and strengthen the market position. For instance, in May 2017, Merck & Co., a pharmaceutical company, received the U.S. Food and Drug Administration Approval (FDA) for Keytruda (pembrolizumab) indicated for the treatment of urothelial carcinoma or also called bladder cancer.
2. Key players in the market are focused on different growth strategies such as research and development, in order expand their product portfolio. For instance, in August 2019, Roche Holding AG, a Swiss healthcare company, announced positive result for Tecentriq (atezolizumab), which meets its co-primary endpoint in Phase III IMvigor 130 trial, indicated for the treatment of bladder cancer.
3. Key players in the market are involved in various growth strategies such as gaining product approval from regulatory authorities, in order expand their product portfolio and enhance their market position. For instance, in February 2017, Bristol-Myers Squibb, a U.S.-based pharmaceutical company, received the U.S. FDA approval for Opdivo (nivolumab) injection for intravenous use, which is indicated for the treatment of urothelial carcinoma or bladder cancer.